These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38842797)

  • 1. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy.
    Sanchez VA; Dinh PC; Monahan PO; Althouse S; Rooker J; Sesso HD; Dolan ME; Weinzerl M; Feldman DR; Fung C; Einhorn LH; Frisina RD; Travis LB
    JAMA Oncol; 2024 Jul; 10(7):912-922. PubMed ID: 38842797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
    Ardeshirrouhanifard S; Fossa SD; Huddart R; Monahan PO; Fung C; Song Y; Dolan ME; Feldman DR; Hamilton RJ; Vaughn D; Martin NE; Kollmannsberger C; Dinh P; Einhorn L; Frisina RD; Travis LB
    Ear Hear; 2022; 43(3):794-807. PubMed ID: 35067571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
    Skalleberg J; Småstuen MC; Oldenburg J; Osnes T; Fosså SD; Bunne M
    Laryngoscope; 2020 Sep; 130(9):E515-E521. PubMed ID: 32065408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
    Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
    J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
    Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
    J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
    Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
    Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.
    Sanchez VA; Shuey MM; Dinh PC; Monahan PO; Fosså SD; Sesso HD; Dolan ME; Einhorn LH; Vaughn DJ; Martin NE; Feldman DR; Kroenke K; Fung C; Frisina RD; Travis LB
    J Clin Oncol; 2023 Apr; 41(12):2211-2226. PubMed ID: 36626694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
    Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
    Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-induced hearing loss after treatment for childhood cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
    Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
    J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
    Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
    Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
    J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
    Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
    BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer.
    Bass JK; Liu W; Banerjee P; Brinkman TM; Mulrooney DA; Gajjar A; Pappo AS; Merchant TE; Armstrong GT; Srivastava D; Robison LL; Hudson MM; Krull KR
    JAMA Oncol; 2020 Sep; 6(9):1363-1371. PubMed ID: 32729886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Hearing Loss Among a Representative Sample of Canadian Children and Adolescents, 3 to 19 Years of Age.
    Feder KP; Michaud D; McNamee J; Fitzpatrick E; Ramage-Morin P; Beauregard Y
    Ear Hear; 2017; 38(1):7-20. PubMed ID: 27556530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
    El Charif O; Mapes B; Trendowski MR; Wheeler HE; Wing C; Dinh PC; Frisina RD; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Gamazon ER; Cox NJ; Huddart R; Ardeshir-Rouhani-Fard S; Monahan P; Fossa SD; Einhorn LH; Travis LB; Dolan ME
    Clin Cancer Res; 2019 Jul; 25(13):4104-4116. PubMed ID: 30952644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
    Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
    Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Self-reported Measures of Hearing With an Objective Audiometric Measure in Adults in the English Longitudinal Study of Ageing.
    Tsimpida D; Kontopantelis E; Ashcroft D; Panagioti M
    JAMA Netw Open; 2020 Aug; 3(8):e2015009. PubMed ID: 32852555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of two word-recognition tasks in multitalker babble: Speech Recognition in Noise Test (SPRINT) and Words-in-Noise Test (WIN).
    Wilson RH; Cates WB
    J Am Acad Audiol; 2008; 19(7):548-56. PubMed ID: 19248731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.